http://rdf.ncbi.nlm.nih.gov/pubchem/patent/RU-2613973-C1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_f5d65415aec835afce8c9d26ad725006 |
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D417-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-506 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P11-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P29-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P25-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D417-14 |
| filingDate | 2015-09-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2017-03-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_91d7d7eebcd658674af727cedda5d004 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d6dd41d392b18f92a48a97bcd6267d9c http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_5b2720433281bae917a227d4326b6f49 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_abc825812ef4488eff87041955d3f44b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_c0b6ada5604ecadbf610f4d221e94a81 |
| publicationDate | 2017-03-22-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | RU-2613973-C1 |
| titleOfInvention | Novel efficient inhibitor of kinase 4, associated with interleukin-1 (irak4) |
| abstract | FIELD: chemistry. n SUBSTANCE: invention relates to a compound of N-(6-((1-((2-ethylpyrimidin-5-yl)methyl)piperidin-4-yl)methyl)pyridin-2-yl)-5-methylthiazol-2-amine or its pharmaceutically acceptable salt, solvate or hydrate. Compound according to invention is intended for preparing a pharmaceutical composition for treating and/or preventing a pathological condition, associated with aberrant activity of IRAK4 kinase. Pharmaceutical composition for treating and/or preventing a pathological condition, associated with aberrant activity of IRAK4 kinase, is characterized by that it contains a therapeutically effective amount of compound according to invention and pharmaceutically acceptable carrier, solvent and/or filler. Pathological condition associated with aberrant activity of IRAK4 kinase is an immune inflammatory disease or oncological disease. n EFFECT: technical result is production of N-(6-((1-((2-ethylpyrimidin-5-yl)methyl)piperidin-4-yl)methyl)pyridin-2-yl)-5-methylthiazol-2-amine or its pharmaceutically acceptable salt, solvate or hydrate as a selective IRAK4 kinase inhibitor. n 13 cl, 10 dwg, 2 tbl |
| priorityDate | 2015-09-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 230.